Advanced search
Publication Cover
Journal of Asthma Volume 60, 2023 - Issue 1
Submit an article Journal homepage
567
Views
5
CrossRef citations to date
0
Altmetric
Articles

Long-term retention rate of mepolizumab treatment in severe asthma: a 36-months real-life experience

Andrea Matuccia Immunoallergology Unit, Careggi University Hospital, Florence, ItalyORCID Iconhttps://orcid.org/0000-0002-8713-4161
, MDORCID Icon,
Emanuele Vivarellia Immunoallergology Unit, Careggi University Hospital, Florence, Italy
, MD,
Susanna Bormiolib Allergology and Clinical Immunology Unit, San Giovanni Di Dio Hospital, Florence, Italy
, MD,
Nencini Francescaa Immunoallergology Unit, Careggi University Hospital, Florence, Italy
, BS,
Fabio Chiccolic Department of Clinical and Experimental Medicine, Unit of Internal Medicine, University of Florence, Florence, Italy
, MD,
Mecheri Valentinac Department of Clinical and Experimental Medicine, Unit of Internal Medicine, University of Florence, Florence, Italy
, MD,
Grosso Francescac Department of Clinical and Experimental Medicine, Unit of Internal Medicine, University of Florence, Florence, Italy
, MD,
Rossi Olivieroa Immunoallergology Unit, Careggi University Hospital, Florence, Italy
, MD,
Paola Parronchic Department of Clinical and Experimental Medicine, Unit of Internal Medicine, University of Florence, Florence, Italy
, MD, phd &
Alessandra Vultaggioa Immunoallergology Unit, Careggi University Hospital, Florence, ItalyCorrespondence[email protected] [email protected]
, MD, phd show all
Pages 158-166 | Received 19 Oct 2021, Accepted 27 Jan 2022, Published online: 12 Feb 2022

Citations (5)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Y. T. Lim, T. C. Williams, R. J. Langley & E. Weir. (2024) Mepolizumab in children and adolescents with severe eosinophilic asthma not eligible for omalizumab: a single Center experience. Journal of Asthma 0:0, pages 1-8.
Read now
Jaclyn Davis, Pamela M. McMahon, Andrew Simon, Katherine Haffenreffer, Aziza Jamal-Allial, Cheryl N. McMahill-Walraven, Anne Marie Kline, Jeffrey S. Brown, Melissa K. Van Dyke, Rupert W. Jakes & Ann Chen Wu. (2023) The association of varying treatment thresholds of mepolizumab on asthma exacerbations in adults. Journal of Asthma 60:12, pages 2198-2206.
Read now

Articles from other publishers (3)

Diego Bagnasco, Benedetta Bondi, Marco Caminati, Stefania Nicola, Laura Pini, Manlio Milanese, Luisa Brussino, Gianenrico Senna, Giorgio Walter Canonica & Fulvio Braido. (2024) Evaluation of Clinical Remission in Best-Performing Severe Asthmatic Patients Treated for Three Years with Mepolizumab. Biomedicines 12:5, pages 960.
Crossref
Diego Bagnasco, Stefania Nicola, Elisa Testino, Luisa Brussino, Laura Pini, Marco Caminati, Federica Piccardo, Rikki Frank Canevari, Laura Melissari, Alessandro Ioppi, Luca Guastini, Carlo Lombardi, Manlio Milanese, Francesca Losa, Michela Robbiano, Laura De Ferrari, Anna Maria Riccio, Giuseppe Guida, Marco Bonavia, Donatella Fini, Francesco Balbi, Cristiano Caruso, Pierluigi Paggiaro, Francesco Blasi, Enrico Heffler, Giovanni Paoletti, Giorgio Walter Canonica, Gianenrico Senna & Giovanni Passalacqua. (2023) Long-Term Efficacy of Mepolizumab at 3 Years in Patients with Severe Asthma: Comparison with Clinical Trials and Super Responders. Biomedicines 11:9, pages 2424.
Crossref
Bruno Sposato, Francesco Bianchi, Alberto Ricci & Marco Scalese. (2023) Clinical Asthma Remission Obtained with Biologics in Real Life: Patients’ Prevalence and Characteristics. Journal of Personalized Medicine 13:6, pages 1020.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.